2017
DOI: 10.1080/00365521.2017.1281434
|View full text |Cite
|
Sign up to set email alerts
|

Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn’s disease

Abstract: Local application of ADSCs resulted in significantly higher fistula closure rate on an animal model. BLI monitoring was proved to be feasible and showed rapid reduction of the ADSC mass after application. More viable cells were detected in animals with healed fistula at the end of the follow-up.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
17
0
3

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(21 citation statements)
references
References 41 publications
1
17
0
3
Order By: Relevance
“…Finally, the full histological remission was not observed in any dog [107]. Moreover, the local application of ASCs was associated with a significantly higher rate of fistula closure in a rat model of perianal fistulas [111].…”
Section: Animal Modelsmentioning
confidence: 89%
See 1 more Smart Citation
“…Finally, the full histological remission was not observed in any dog [107]. Moreover, the local application of ASCs was associated with a significantly higher rate of fistula closure in a rat model of perianal fistulas [111].…”
Section: Animal Modelsmentioning
confidence: 89%
“…Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn's disease [111] Prospective, randomized, controlled study 32 rats Perianal fistula model Allogeneic Ryska,…”
Section: Human Ascsmentioning
confidence: 99%
“…In previous human studies for other conditions, systemic adverse effects such as infections and viral reactivation secondary to immune suppression occurred less frequently with local application of cells as compared to systemic application [73, 74]. Although both IP and intravenous (IV) routes of administration had equivalent efficacy in an animal model, many cells become entrapped in the lungs after IV injection, leading to a reduction in the number of cells available for therapeutic purposes [14, 75, 76].…”
Section: Clinical Applicationsmentioning
confidence: 99%
“…AD-MSCs were used in this induced CD mice model where systemic infusion of AD-MSCs improved the clinical and histopathologic severity of colitis, reduced diarrhea and inflammation, and increased mice survival. This study found that AD-MSCs down-regulated Th1-driven inflammatory responses which subsequently decreased the production of inflammatory cytokines and chemokines [19]. In another study dogs with perianal fistulas were treated intralesionally with 2 × 107 human embryonic stem cell derived MSCT.…”
Section: Animal Studiesmentioning
confidence: 81%